Astrana Health Inc

This management proposal asks shareholders to cast a non-binding advisory vote approving the company’s executive compensation as disclosed. Management seeks this vote to comply with Dodd-Frank/SEC rules and to obtain stockholder feedback; the Board and Compensation Committee view prior strong support (about 91% in 2025) as validation and intend to consider results when setting future pay. The proposal does not change compensation directly but influences governance and executive pay accountability. The Board recommends a vote FOR, stating the program incentivizes performance and aligns executives with stockholders, and emphasizes the program’s features: performance-based bonuses tied to revenue, adjusted EBITDA, and wellness visit metrics; significant equity-based long-term incentives with performance and time-based vesting; clawback policy; and stock ownership guidelines. While non-binding, a substantial negative vote would likely prompt the Compensation Committee to engage with major stockholders and could lead to design changes; however, the company expects continued support given recent high approval and disclosed pay-for-performance alignment. Company-specific context includes large equity awards to executives, recent acquisition activity (Prospect Health) affecting scale, and double-trigger change-of-control protections in equity plans that may be scrutinized by investors.

This management proposal requests shareholder approval to amend and restate the company’s long-term equity incentive plan to add 1,000,000 shares to the reserve (an increase from 4.1M to 5.1M) and extend the plan’s term by roughly one year. Management frames the change as necessary to continue granting equity awards to attract, retain, and reward employees, executives, and non-employee directors, citing historical grant usage (about 940,807 shares remaining as of the record date) and an estimate that the increase would support roughly two years of grants under current practices. The amended plan retains investor-friendly features: minimum vesting (one year, with limited 5% exception), no liberal share recycling, limitations on director annual compensation, prohibition on repricing without shareholder approval, double-trigger change-of-control vesting, no discounted options, clawback policy, and limits on share counting for SARs; it also allows performance- and time-based awards administered by an independent committee. The board recommends FOR, arguing the plan aligns executives with shareholder interests and is competitive in the talent market. Key governance considerations for an analyst include the size of the requested increase relative to total shares outstanding (~55.7M), historical burn rate and dilution prospects, the board’s anti-dilution and anti-repricing protections, the presence of double-trigger change-of-control protections (which some investors scrutinize), and the plan’s minimum vesting and 5% exception. Given recent large equity grants to executives and significant outstanding unvested awards, shareholders should evaluate potential dilution, the company's burn-rate metrics, and whether future awards will be subject to rigorous performance metrics and retentive vesting schedules.